8-K: Myomo Announces Record Preliminary Q2 2024 Revenues, Surpassing Expectations

Myomo reports record preliminary second-quarter revenues of $7.2 million to $7.4 million, significantly exceeding previous expectations and marking a substantial increase from the first quarter.

Summary

• Myomo, Inc. has announced preliminary results for the second quarter of 2024, showing record revenues between $7.2 million and $7.4 million.
• This represents a 92% to 97% increase compared to the first quarter of 2024.
• The company also saw a record number of revenue units, estimated to be between 155 and 160, a 70% to 76% increase from the 91 units in the previous quarter.
• Pipeline additions reached approximately 550, and authorizations and orders hit around 210, both record highs.
• Faster than anticipated payments from the Centers for Medicare & Medicaid Services (CMS) contributed to the strong results.
• Myomo also expects to have substantially met its hiring objectives for the first half of the year, ending the quarter with nearly 150 employees.
• Effective July 1, 2024, Myomo began recording revenue for Medicare Part B patients upon product delivery.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to record revenues, significant growth, and exceeding expectations. The company's strong performance and positive outlook suggest a high level of confidence.

Positives

• The company achieved record quarterly revenues, significantly exceeding previous expectations.
• There was a substantial increase in revenue units compared to the previous quarter.
• Myomo experienced record pipeline additions, authorizations, and orders.
• Faster payments from CMS contributed to the positive financial results.
• The company is on track with its hiring objectives, increasing its capacity for growth.
• The change in revenue recognition for Medicare Part B patients is expected to positively impact future financial results.

Risks

• The company's ability to obtain sufficient reimbursement from third-party payers is a risk.
• Myomo needs to navigate factors to grow revenues sufficiently to achieve operating cash flow breakeven.
• Revenue concentration with a particular insurance payer is a potential risk.
• Supply chain disruptions could impact the delivery and fitting of custom devices.
• The company depends on external sources for financing if it does not achieve cash flow breakeven.
• There are risks associated with maintaining strategic collaborations and executing the business plan.
• The company faces competition in a highly competitive and evolving industry.
• General market, economic, environmental and social factors could affect the business.

Future Outlook

Myomo expects to report full financial results and operating metrics for the three and six months ended June 30, 2024, as well as its expectations for third quarter and full year 2024 financial results, during the second week of August 2024.

Management Comments

• Paul R. Gudonis, Myomo's chairman and CEO, stated that payments from CMS were much faster than anticipated.
• David Henry, Myomo's CFO, noted that with an established claims payment history from Medicare Part B beneficiaries, they began recording revenue for these patients upon product delivery as of July 1, 2024.

Industry Context

Myomo's announcement reflects a positive trend in the medical robotics and wearable technology sector, where companies are increasingly focusing on innovative solutions for neurological disorders and upper-limb paralysis. The company's success in securing Medicare reimbursements is a key factor in its growth.

Comparison to Industry Standards

• Myomo's 92% to 97% sequential revenue growth is significantly higher than the average growth rate for medical device companies, which typically see single-digit or low double-digit growth.
• Companies like Ekso Bionics and ReWalk Robotics, which also focus on wearable robotics, have not reported similar levels of sequential growth in recent quarters.
• The record pipeline additions and authorizations suggest strong market demand for Myomo's MyoPro product, indicating a competitive advantage in the upper-limb rehabilitation market.
• The faster-than-expected CMS payments highlight Myomo's success in navigating the complex healthcare reimbursement landscape, a challenge for many medical device companies.

Stakeholder Impact

• Shareholders are likely to react positively to the record revenue and growth figures.
• Employees may benefit from the company's growth and hiring initiatives.
• Customers, particularly those with neurological disorders, will benefit from the increased availability of MyoPro devices.
• Suppliers may see increased demand for their products due to Myomo's growth.
• Creditors may view the company more favorably due to its improved financial performance.

Next Steps

• Myomo will report full financial results and operating metrics for the three and six months ended June 30, 2024, in the second week of August 2024.
• The company will also provide its expectations for third quarter and full year 2024 financial results in the same report.

Key Dates

Keywords

Myomo, medical robotics, wearable technology, neurological disorders, upper-limb paralysis, MyoPro, revenue, Medicare, CMS, reimbursement, pipeline, authorizations, orders